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Abstract
Over the years, tireless efforts of the concerned scientists have produced various
new therapeutics and methods for the treatment of bacterial infections. However,
despite the vast regimen of modern antibiotics being corroborated, the diseases
caused by the Gram-positive and -negative pathogens has become untreatable,
mainly due to the constantly evolving threat of antimicrobial resistance (AMR),
thereby leading to huge morbidity and mortality. Moreover, shortage of efficient
therapies, lack of successful prevention strategies and availability of only a few
effective antibiotics urgently necessitated the development of novel therapeutics
and alternative antimicrobial treatments. These developments have been based on
the molecular mechanisms of resistance posed by the pathogens during their inter-
actions with the host. Herein, we collate four essential bacterial components like
chaperones, efflux pumps, two-component systems and biofilms which can present
challenges for the most coveted control of infection. Essentially, we discuss the
current knowledge status of these components to provide insight into the complex
regulation of virulence and resistance for some medically important multidrug-
resistant (MDR) pathogens. This will help the future scientists to clearly focus on
some specific proteins to be targeted by against the available class of drugs and/or
antibiotics with the broader perspective to develop novel antimicrobial agents.
Keywords: antimicrobial resistance, biofilms, chaperones, efflux pumps,
multidrug resistance, two-component systems
1. Introduction
Bacterial infections have been threatening human population since time imme-
morial. Being one of the leading causes of morbidity and mortality (Figure 1), the
latest global rise in antibiotic resistance threatens to undo decades of progress in
treating such bacterial infectious diseases caused by the pathogens. In fact,
multidrug resistance (MDR) conferred by Gram-positive and -negative bacteria is
difficult to treat and may even be, untreatable with conventional antibiotics. The
case has turned out to be so serious that many of these microorganisms are at least
resistant to a single drug regimen while several are moving from developing MDR
to extensively and total drug resistance, referred to as XDR and TDR, respectively.
All the aforementioned classes of resistance, namely MDR, XDR and TDR,
commonly referred to as antimicrobial resistance (AMR), has been conferred the
main cause for the second leading global disease burden of bacterial infection in the
twenty-first century, as reported by WHO [1]. Importantly, the development of
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antibiotics has directly influenced the initial resistance caused by using newer
agents. Moreover, the discovery of new antibiotic classes is reported to be void since
1987, when lipopeptides was the last class introduced (Figure 2) [2]. Thus, it has
become increasingly difficult to find therapeutic options to treat organisms devel-
oping AMR, such as Acinetobacter baumannii, Proteus mirabilis and Pseudomonas
aeruginosa [2]. Nevertheless, antimicrobials have had a significant positive effect on
the administration of irresistible infections and have become a basic component of
all perspectives of modern healthcare.
The rise of AMR development has become a serious concern more than what can
be even perceived. This is potentiated by different facts ranging from adverse
effects of existing antibiotics and consequent re-purposing and/or chemical
modification or their withdrawal leading to the sparing usage of new ones due to
resistance concerns and ultimately a shortage in the development of new antibiotics
[3–5]. Moreover, environments of hospitals and other health care systems as well as
social communities and advanced transport systems have enabled the spread of
AMR easier and faster [6]. This is evidenced by a recent increase in the carbapenem
resistance (e.g. meropenem) due to the presence of carbapenemase, a.k.a. New
Figure 1.
Rates of infection (left) vs. mortality (right) statistics as per National Center for Health Statistics (CDC),
2017.
Figure 2.
The timeline of the development of different antibiotic classes.
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Delhi metallo-β-lactamase-1 (NDM-1) in various Enterobacterales isolates [7].
Initially reported to have found in a patient in Sweden in 2008 who had originated
from India, such cases were found later in UK patients having either travel or
ancestral history from the Indian subcontinent [6]. A variation of no such travel or
hospital contacts, for patients harboring NDM-1, was also reported by 2011 [8],
along with drinking water and sewage samples containing a range of NDM-1 har-
boring bacteria (e.g. Shigella boydii and Vibrio cholerae) [9] thereby proving that
AMR development varies within organism and with the mechanism of transfer of
mobile resistance elements between species (Figure 3). Again, some vaccine
resistance phenomenon has added on to activities while researchers are aiming to
produce advanced vaccines through recombinant DNA technology, keeping in
mind the utility of vaccines over antibiotics (Figure 3).
2. The causes
AMR is exhibited when a microorganism survives in the presence of an antibi-
otic concentration that is generally adequate to prevent or stop its growth. Thus, in
clinical terms “prone” and “resistant” are generally used to infer the efficacy or
failure of medical therapy, respectively [10]. Moreover, the microbes can either be
inherently resistant to an antibiotic or develop resistance after their exposure to
incorrect and/or insufficient dosage prescription. This is commonly the case for
patients routinely communicating with hospital settings thereby having gradually
increased resistance to frequently used antibiotics. For these cases of hospital-
acquired infections (HAI), certain bacteria develop drug-resistant strains through
natural selection mechanism which promotes the persistence of bacterial strains
having acquired some mutation [11]. However, the increased profile of these
pathogens with AMR varies, even though they arise from similar causes.
AMR resistance may evolve as a mechanistic consequence of gene mutation or
direct gene transfer, the latter being also known as horizontal gene transfer (HGT).
Of these two, HGT helps to acquire new resistance genes and virulence determi-
nants through a multitude of mechanisms including conjugation, transduction or
transformation among related and/or non-related species [10]. This phenomenon is
Figure 3.
Antibiotic vs. vaccine-resistant phenomenon. HGT represents horizontal gene transfer, green and red colored
cells denote antibiotic-sensitive and -resistant bacteria, respectively.
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commonly associated with bacterial adaptation to new niches or lifestyles and has
an impact on the development of its genomic content. Again, HGT, with the help of
mobile genetic elements (MGEs) like transposons, has been reported to have con-
ferred resistance to a broad range of antibiotics, particularly toward new ones.
Moreover, transmissible plasmids and phages often bear genes that confer antibiotic
resistance to one or more distinct antibiotics and facilitate their transfer across
different genera. Such evolution essentially underpins the survival of the develop-
ing MDR strains and may be a major reason for the global outbreaks.
3. The effectors
Besides the emerging species of bacteria exhibiting MDR, namely Salmonella
enterica, Mycobacterium tuberculosis and P. mirabilis, other common species of MDR
bacteria responsible for two-thirds of all HAIs are defined by the acronym ESKAPE
to denote the six pathogens namely, Enterococcus faecium, S. aureus, Klebsiella
pneumoniae, A. baumannii, P. aeruginosa and Enterobacter spp. [12]. These are easily
distinguishable from other pathogens due to their enhanced resistance to frequently
used antibiotics such as penicillin, vancomycin, carbapenems and more. One of the
common resistance mechanisms involves enzyme production that alters the antibi-
otic target sites and results in no binding activity with efflux pumps [13]. Efflux
pumps are the characteristics of the Gram-negative bacterial membrane that
enables them to constantly pump out foreign materials, including antibiotics, such
that the intracellular milieu does not have sufficiently elevated drug concentration
to make the effect [13]. Moreover, biofilms are a combination of different microbial
and polymer groups that protect the bacteria from antibiotic therapy by acting as a
biological barrier [13].
3.1 Salmonella enterica
Human infections due to S. enterica, a bacterial pathogen, constitute significant
food borne disease burdens of blood stream associated with a high mortality ratio
throughout the world [14, 15]. S. enterica are the Gram-negative facultative anaer-
obe that belongs to the family Enterobacteriaceae. From over 2,500 strain types, the
strain S. enterica serovar Typhi causes the typhoid fever [16]. Infections with Sal-
monella in humans typically range from non-typhoidal salmonella (NTS) to
typhoidal fever, which can be life-threatening. Additionally, the resistant serovars
causing enteric fever, namely, Typhi, Paratyphi A, B, or C are broadly referred to as
typhoidal Salmonella serovars [14]. However, these are highly adapted to the
human host that is used as their exclusive reservoir [17].
The initial AMR acquired by Salmonella was to the first-line drugs such as
ampicillin, chloramphenicol and sulfamethoxazole. The AMR mechanisms in S.
Typhi include drug inactivation, target site modification and active efflux, which
might be chromosomal or plasmid-mediated [18]. In fact, the resistance of Salmo-
nella and pathogenic E. coli along with other Gram-negative bacteria, against anti-
biotic and non-antibiotic compounds, is related to efficient efflux pumps, which
reduces the intracellular concentration of such compounds [19, 20]. The occurrence
of plasmid-mediated antibiotic resistance to fluoroquinolones has recently been
recorded and referred to a single point mutation in the topoisomerase gene gyrA,
encoding DNA gyrase. Moreover, pathogenic Salmonella uses the two-component
systems (TCS) namely, PhoPQ, PmrAB and Rcs regulatory system for lipopolysac-
charide (LPS) modification and increases the resistance toward host human AMPs
[18], which could help it to survive in vivo and develop the disease [21]. The lack of
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such systems in the eukaryotic host made them eligible to be targeted by anti-
virulence compounds. This strategy was rendered successful during selective active
site inhibition of PhoQ autokinase activity by Quinazoline [22]. Furthermore, for
cells lacking an RNA chaperone, known as bacterial cold shock proteins (CSPs),
high levels of porin genes viz. ompD, ompF, and ompC resulted in increased cell
membrane permeability in response to bile salt stress [23]. This finding highlights
on the importance of the chaperone protein in the maintenance of the membrane
integrity and selective permeability.
3.2 Proteus mirabilis
P. mirabilis, the Gram-negative uropathogenic bacteria and a member of the
Enterobacteriaceae family, is developing MDR to antibiotics and biofilm formation.
This may trigger significant complications in patients with long-term catheters or
urinary tract infections (UTI) [24, 25]. Salmonella genomic island 1, an integrative
mobilizable component of multidrug-resistant S. Typhimurium, was recently iden-
tified in a remarkably high proportion of P. mirabilis clinical isolates from France,
indicating its involvement in the spread of this MDR element [26]. P. mirabilis is
susceptible to aminoglycosides, fluoroquinolones, sulfamethoxazole and β-lactams,
but resistant to tetracycline and nitrofurantoin [27]. This enhanced resistance to
antimicrobial agents has resulted not only in modifications to antimicrobial thera-
pies, but also in poor diagnosis and increased mortality rate of nosocomial infections
[28]. Astonishingly, in 2016, a new isolate of P. mirabilis, from diabetic ulcer
patient, have shown a remarkable resistance to silver nanoparticles, spreading the
alarm of resistance to even include metallic nanoparticles like silver [29]. Moreover,
the efflux pumps (EPs) also play important role in P. mirabilis drug resistance, as
exemplified of the increased cell permeability of the EP inhibitor Phenylalanine-
Arginine Beta-Naphthylamide (PAβN), thereby making it more susceptible to
acetylsalicylic acid [30].
3.3 Acinetobacter baumannii
A. baumannii are the most successful Gram-negative opportunistic nosocomial
pathogens responsible for hospital-acquired infections (HAI) in intensive care
units. The WHO has stated A. baumannii to be one of the most serious ESKAPE
organisms that have effectively escaped the effects of antibiotics [31]. Several resis-
tance mechanisms are known, including target modifications, multidrug efflux
pumps, enzymatic degradation or modification of drugs and permeability defects
besides some other uncategorized ones [31]. A. baumannii strain isolates are resis-
tant to cephalosporins and penicillins, including inhibitory combinations of
aminoglycosides and fluoroquinolones [32]. Moreover, some A. baumannii strains
can acquire families of EP from other species and new β-lactamases to improve the
resistance of β-lactam antibiotics [11]. Furthermore, A. baumannii clinical isolates
are reported to be resistant to colistin developed due to a modification of the lipid A
component of the lipopolysaccharide outer membrane. The modification is medi-
ated by the TCS PmrAB and a mutation of the LpxA/C/D gene [33]. Such resistance
mechanism through LPS modification brings out the importance of the TCS in
A. baumannii.
3.4 Staphylococcus aureus
S. aureus is a major Gram-positive pathogen, both within the hospital settings
and environmental communities and reported to be prone to nearly any antibiotic
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ever produced [34]. Such multiple antibiotics resistance has developed by acquiring
MGE through HGT. This results in mutations that alter drug binding sites on
molecular targets leading to an increase in the expression of endogenous efflux
pumps. These resistant strains fight antibiotics by deactivating β-lactam binding
proteins [11]. Due to its increasing antibiotic resistance to penicillin and methicillin,
the bacteria remain a growing pandemic through mechanisms including HGT and
antibiotic alterations [35]. Moreover, S. aureus is not far from the Gram-negative
bacteria which are resistant to antibiotics mediated by TCS. Thus, the TCS VanRASA
regulates the necessary mechanism of resistance in vancomycin resistance S. aureus
(VRSA) [36]. Again, the EPs from S. aureus have been categorized recently in six
different diverse groups. They were found to be either chromosomal or extrachro-
mosomal except qacA/B and smr which were found only on the studied plasmid
samples [37].
3.5 Pseudomonas aeruginosa
P. aeruginosa, the Gram-negative nosocomial pathogen, is considered as an epit-
ome of AMR due to its major involvement in causing chronic and nosocomial
diseases. This high rate of resistance is directly related to their various inherent
resistance mechanisms expressed, including the down-regulation of porin
manufacturing system (carbapenems and cefepime), overexpression of efflux
pumps (carbapenems) or production of other beta-lactamases besides the high
production of AmpC beta-lactamase. The most frequently administered
antipseudomonal antibiotics are aminoglycosides, fluoroquinolones and β-lactams
that are susceptible to the known resistance mechanisms in P. aeruginosa. Its
mutants, with upregulated EPs, have been reported that makes it difficult to find an
effective antibiotic [38]. Moreover, only inhibition of the EP, in the recent clinical
MDR isolates, has almost no effect in increasing susceptibility toward the tested
antibiotics [39]. However, inhibition of histidine kinases (HKs), a part of TCS,
using benzothiazole-based HK inhibitors, resulted in a reduced production of mol-
ecules which are linked to quorum-sensing and redox-balance. It also
showed reduced motility and attachment ability, rendering it to be less
virulence [40].
3.6Mycobacterium tuberculosis
Tuberculosis (TB) poses serious global health crisis as an important chronic
infectious disease caused by strains of M. tuberculosis (MTB). It is an extremely
dangerous human pathogen that infects one-third of the world’s population and
causes almost two million fatalities each year [41]. Besides that, the total number of
cases have been still increasing, due to strains of MTB being resistant to first-line
drug therapy [41]. This involves resistance to the two most powerful anti-TB drugs,
rifampicin and isoniazid, thereby evoking the title of multidrug resistance TB
(MDR-TB). The existence of even more resistant MTB strains has been described as
extreme drug-resistant (XDR)-TB, which shows resistance against the injectable
second line drugs such as kanamycin, amikacin or capreomycin [42]. A more
alarming situation has arisen with the depiction of MTB strains showing resistance
to all antibiotics available for testing, with the species being termed as total drug
resistant (TDR)-TB [43]. Therefore, the early onset of detection and prevention of
MDR-TB, will enable the therapeutic treatment to reduce the spread of infection.
Thus, a better understanding of the mechanisms of action of anti-TB drugs will
facilitate the development of new drug targets aimed at improving outcomes from
diseased patients [44]. In fact, it has been found that MprA, part of TCS MprAB.
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along with other TCS, namely, TrcRS, control the expression of antibiotic resistant
related β-propeller gene Rv1057 [45, 46]. The roles of chaperone(s) in the resistance
ofM. tuberculosis are yet to be declared.
3.7 Klebsiella pneumoniae
K. pneumoniae is a Gram-negative hospital-acquired pathogen causing nosoco-
mial pneumonia and urinary tract infections. The increased incidence of
carbapenemase-producing and thus, carbapenem resistant K. pneumoniae (CRKP),
has posed a major threat to global human health. Diseases caused by CRKP were
treated successfully in combination therapies of antimicrobial agents [47]. It has
been reported that tigecycline and the polymyxins (polymyxin B or colistin)
showed variable susceptibilities to treat infections caused by CRKP [4]. This has led
to the emergence of CRKP, against which there are very few antibiotics in develop-
ment that can treat the infections [11]. Incidentally, the minimum inhibitory con-
centration (MIC) of eravacycline has been increased as a consequence of increased
expression of two EP complexes OqxAB and MacAB in K. pneumoniae [48], which
suggests their contribution to resistance against this antibiotic.
3.8 Enterococcus faecium
Generally associated with HAI in immunocompromised patients, E. faecium is a
Gram-positive bacterium, often showing resistance to β-lactam antibiotics, includ-
ing penicillin and other antibiotics of last resort. Reportedly, there has also been an
increase in vancomycin-resistant enterococci (VRE) strains, exhibiting resistance to
vancomycin-A [11]. These VRE strains show an ability to produce and share their
resistance through HGT, as well as code for virulence factors that regulate pheno-
types. These virulence phenotypes differ from the wild types in producing thicker
biofilms for development in a variety of environments, including medical devices
such as urinary catheters and cardiovascular prosthetic valves [14]. The thicker
biofilms function as a “mechanical and biochemical shield” that protects the bacte-
ria from antibiotics and is the most efficient protective system against bacterial
treatment [13]. In fact, the intensive use of antibiotics in animal rearing resulted in
the development of resistance in E. faecium [49]. Moreover, recently, a study
identified few new antibiotics resistance genes related to EP, namely, optrA and
poxtA besides the new gene cfr-like variant in E. faecium [50]. Earlier, the expres-
sion of the EP proteins, EfrAB, has been shown to be increased upon halving the
MIC of gentamicin and got lowered upon the addition of 3 mM EDTA [51]. Fur-
thermore, TCS like ChtSR has been found to be responsible for chlorhexidine
tolerance in MDR E. faecium, upon testing by targeted deletion mutation of chtR and
chtS genes [52]. Again, the TCS CroRS was reported to be crucial in resistance to cell
wall antibiotics in E. faecium [53].
3.9 Enterobacter
Enterobacter are Gram-negative bacterial species which trigger UTI and blood
diseases. They show resistance against different drug therapies, thus, requiring the
development of new and efficient antibiotic treatments [54]. In fact, colistin and
tigecycline are, only two of the antibiotics, presently being used as medication while
no other feasible antibiotics are apparently being developed. Other most commonly
reported antimicrobials in Enterobacter infections are aminoglycosides, cephalospo-
rins, carbapenems and fluoroquinolones. Moreover, in some species, a 5- to 300-
fold rise in the MIC was reported when subjected to several gradually increasing
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benzalkonium chloride concentrations [55]. In fact, the EP protein, SugE, in
Enterobacter cloacae, which is a member of small multidrug resistance (SMR) pro-
tein family, has been found to be responsible for resistance against toxic compounds
such as cetylpyridinium chloride and benzalkonium chloride [56]. Another EP
protein of the resistance nodulation cell division (RND) category, AcrB, has also
been found to be very essential in the pathogenicity and antibiotics resistance of
E. cloacae [57, 58].
4. The role players
Several health interventions have been proposed as alternatives to current anti-
biotic therapy and prevent the resistant mechanisms of which, the development of
new drug classes, use of vaccines or other therapeutic strategies are noteworthy
(Figure 4) [59]. In fact, using computational approaches, certain proteins and/or
phenotypes, having plausible involvement in antibiotic resistance, are proposed
[60–64] as discussed below.
4.1 Chaperones
Bacterial chaperones like DnaK, belonging to the heat shock proteins (Hsp)70
family, are produced by cells in response to exposure to stressful conditions [65].
The interaction between the two domains of such Hsp70, namely ATPase and the
substrate-binding domain, triggers the chaperone-based activity of DnaK which are
also enhanced by the co-chaperone such as DnaJ (Hsp40 family) and chaperone
GroE (Hsp60 family) [66]. DnaK acts on unfolded and partially folded protein
chains by binding and controlling their configuration [67].
Besides stress response, DnaK plays a significant housekeeping role in
maintaining normal bacterial cellular growth and homeostasis [68]. Thus, any
Figure 4.
Alternative strategies to combat antimicrobial resistance and their mechanisms of action.
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alterations in the dnaK gene reduce the growth of bacteria within the host [69]. In
fact, during infection, bacteria activate their heat shock genes like DnaK to protect
their cellular machinery from the consequently activated host immune system for
defense mechanisms and thereby strengthen their virulence strategy [69]. This
phenomenon, thus, provides an insight into structural mechanism of DnaK, leading
to misfolding and its role in controlling protein activity contributing to the patho-
genicity of multidrug-resistant bacteria, such as the opportunistic human pathogen
A. baumannii [70]. In fact, DnaK mutants showed decreased viability and improved
susceptibility under strained circumstances during systemic infection as reported
for dnaK mutants of S. aureus with increased sensitivity to oxacillin and methicillin
[71] and dnaK/dnaJ mutants of E. coli having increased sensitivity to
fluoroquinolones [72].
4.2 Efflux pumps
Antibiotic resistance can be triggered, in MDR bacteria, by four discrete mech-
anisms viz. target modification, reduced permeability and improved efflux, drug
inactivation and drug extrusion by the multidrug efflux pumps (EP) [73]. Due to
their poly-substrate specificity, besides having the potential to expel a broad variety
of antibiotics, these EP also manage the development of other resistance mecha-
nisms by decreasing intracellular antibiotics concentration and stimulating muta-
tion accumulation [73]. Consequently, over-expression of multidrug EP is involved
with clinically related antibiotic resistance. Thus, there has been increasing evi-
dence of EP having biochemical functions in bacteria along with their appearance
under strict regulations in response to some physiological and environmental sig-
nals [73]. Hence, a systematic knowledge of EP is important for the development of
EP inhibitors as promising AMR intervention strategies.
EP are present in almost all bacterial species involved in AMR. They can be
located on plasmids or chromosomes that encode this class of proteins. The five
families of bacterial EP, found to be involved in MDR, are the major facilitator
superfamily (MFS), the multidrug and toxic compound extrusion (MATE) family,
the ATP-binding cassette (ABC) superfamily, the small multidrug resistance (SMR)
family, and the resistance-nodulation-division (RND) family, based on their com-
position, energy sources and substrates used [73]. Importantly, only RND super-
family is found in Gram-negative bacteria due to its structure containing tripartite
complex and the efflux systems of the other four families are widely distributed in
both Gram-positive and -negative bacteria. These EP can be either single or
multiple-component transporters depending on their specific classes. They com-
prise both an inner and an outer membrane transporter, like the RND type. It has
been found that RND family pumps are frequently associated with therapeutically
important bacterial resistance such as AcrB in S. Typhimurium and E. coli and MexB
in P. aeruginosa owing to their tripartite complex, enabling various drugs to be
immediately extruded from cytoplasm to outside the bacterial cells [74].
In fact, antibiotics such as fluoroquinolone, tetracycline, rifampin, novobiocin,
chloramphenicol and B-lactams were used to analyze the substrate profile of
housekeeping efflux system AcrAB-TolC in E. coli [74]. Similarly, the S.
Typhimurium AcrAB-TolC efflux system was also capable of expelling various
antibacterial agents such as tetracycline, quinolones and chloramphenicol [75, 76].
The two RND efflux pumps, MexAB-OprM and MexXY-OprM, homolog to AcrAB-
TolC system in E. coli, are also expressed in P. aeruginosa. Thus, these systems can
actively export chloramphenicol, tetracycline and fluoroquinolones. In addition to
these substrates, MexAB-OprM export B-lactams and novobiocin whereas MexXY
system exports aminoglycosides (Table 1) [77].
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4.3 Two-component systems
Two component systems (TCS) are commonly found in bacteria, allowing them
to respond to various fluctuations in the environment. Canonically, TCS are com-
posed of a response regulator (RR) and a histidine kinase (HK) [78]. The membrane
associated HKs can detect and transform various environmental sensations by
autophosphorylation. The HKs can then transphosphorylate their cognate partners,
the RRs, which then influence the expression of downstream genes to affect the
concerned phenotype [78].
A thorough investigation of the correlation between efflux pumps and TCSs in
E. coli, revealed the involvement of several RRs in drug resistance [79]. Among
them, mdtABC and acrD expression was triggered by the BaeSR and CpxAR TCS
in response to indole [80, 81] and envelope stress [79], respectively, while no
signals were detected when the EvgSA TCS triggered the activation of EmrKY and
MdtEF [82, 83]. Moreover, the expression of the MdtEF efflux pump was
Efflux pump Pump type Regulator Regulator family Inducible signal
Acinetobacter baumannii
AdeABC RND AdeRS TCS 
Pseudomonas aeruginosa
MexXY RND MexZ TetR Tetracycline, erythromycin, gentamicin
MexAB RND MexR MarR Superoxide stress
NalD TetR 
MexCD RND NfxB LacI/GalR Biocide chlorhexidine
MexEF RND MetT LysR Chloramphenicol, GSNO
Salmonella Typhimurium
AcrAB RND MarA AraC 
RamA AraC Indole, bile salts
RamR TetR 
SoxS AraC 
AcrR TetR 
AcrD RND BaeSR TCS Indole, zinc, copper
CpxAR TCS Indole, zinc, copper
AcrEF RND AcrS TetR 
MdtABC RND BaeSR TCS Indole, zinc, copper
CpxAR TCS Indole, zinc, copper
MacAB ABC PhoQP TCS Magnesium
MdsABC RND GolS MerR Gold
Staphylococcus aureus
MepA MFS QacR TetR Rhodamine 6G, TPP
QacA MATE MepR Chlorhexidine, cetrimide, dequalinium
Adapted from [73].
 means unknown.
Table 1.
Selected multidrug resistance efflux pump regulators.
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triggered by ArcAB-TCS system in the M9 glucose medium [84, 85]. Similar to
E. coli, MdtABC and AcrD are also stimulated by the Salmonella BaeSR TCS in
response to metal ions [86].
Again, PhoPQ TCS, the core virulence regulator in Salmonella, controls the
activation of the RND type MacAB pump [89, 90]. TCS was also revealed to be
involved in regulating efflux pumps in other species. In A. baumannii, the expres-
sion of RND type efflux pump AdeABC has been reported to be regulated by
AdeRS-TCS (Table 2). The AdeRS-TCS regulatory system is encoded by adeRS
genes, being positioned in the upstream region of adeABC genes [91]. Inactivation
of AdeR or AdeS resulted in A. baumannii being susceptible to aminoglycosides
which are the substrates of this pump, indicating the vital role of AdeRS in adeABC
activity. The nature of these inducing signals and the AdeRS activation mechanism,
however, remain unclear [92].
TCS can play an important role in drug discovery. There are several ways to
target TCS proteins. Of these, the structure-based virtual screening (SBVS) analysis
is carried out using compound databases containing a broad range of prospective
inhibitors, including structures known to be antibacterial [93].
4.4 Biofilms
Biofilms, in both single and multi-species groups, communicate and cooperate to
perform complex processes with each other and their environment [94]. With the
scientists aiming to understand the intercellular interactions that encourage the
development of biofilms, they are presently a serious health issue, playing a major
role in abiotic device-related diseases such as catheters, prosthetic valves and con-
tact lenses [95].
Biofilm formation can be explored in different stages comprising (a) distinctive
adhesion of the planktonic bacteria (PB) to a solid surface [96], (b) micro-colonies
Bacteria Inhibitors TCS Mechanisms Reference
Salmonella enterica
Typhi and/or
Typhimurium
XR770 BaeSR
OmpR/
EnvZ
Inhibition of key interacting residues of
DHp domain of HK
[87]
NSC9608 (8
compounds,
NCI library)
PhoP-Q Inhibition of formation of the PhoP-DNA
complex
[88]
Pseudomonas
aeruginosa
Thiazole
derivatives
Algr1-2 Inhibition of phosphorylation/
dephosphorylation of Algr2 Inhibition of
DNA-binding activity of Algr1
[88]
Enterococcus
faecium
Thiazole
derivatives
VanR-S Inhibition of autophosphorylation [88]
Staphylococcus
aureus
Walkmycin B
and
Waldiomycin
WalK-R Binds to the HK cytoplasmic domain for
the inhibition of autophosphorylation
[88]
Salicylanilide KinA/
Spo0F
Affects membrane fluidity, disturbing
signal transduction
[88]
Methicillin-resistant
Staphylococcus
aureus
Bis-phenol VanR-S — [88]
Table 2.
Representative TCS targets with their known inhibitors.
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(MC) formation surrounded by protective secreted molecules known as the matrix
of extra polymeric substances (EPS) having up to 97% water as the main compo-
nent [97] and (c) dispersal including shedding of PB or MC from the mature biofilm
[97]. The last phase can encourage further biofilm colonization of the host which
can eventually benefit the bacteria with a limited supply of nutrients and waste
accumulation [97]. Importantly, the transition from planktonic growth to surface
life is triggered by several environmental signals known as various stresses for the
bacteria based on their ecological niche [98]. These include UV radiation, pH
changes, oxygen tension, osmolarity, iron availability, temperature, nutrient supply
and desiccation [98], which may disrupt their fundamental functions such as
growth and survival capability. The environmental indications, however, vary sig-
nificantly between organisms. Thus, P. aeruginosa will form biofilms under most
circumstances [99, 100] while E. coli O157:H7 produce a biofilm under low-nutrient
conditions only [101].
Recent advances in biofilm research have proven its connection to various path-
ways and proteins [61]. For instance, defects in MDR EP activity reduced the
biofilm formation and thus, EP inhibitors have been employed as a promising
biofilm inhibition approach for strains of E. coli and Klebsiella [102], Salmonella
[103], P. aeruginosa and S. aureus [104]. However, certain other reports show that
despite the elimination of planktonic cells through pharmacological intervention,
the sessile forms are resistant and continue to proliferate within the biofilm [105].
This is more of prominence on abiotic surfaces [95], such as catheters [106], contact
lenses [107] and prosthetic cardiac valves [108]. Thus, alginate mucoids, with EPS
overexpression, from P. aeruginosa species isolated from cystic fibrosis patients,
were found to improve AMR by promoting the biofilm formation [109].
5. Conclusion
The constant increase in AMR is a significant public health concern that needs to
be addressed now. This review starts with an introduction to AMR followed by the
threats from the clinically important MDR pathogens and their rise. With the
existing management strategies for MDR by the scientists still ongoing, we have
taken up this study to propose an integrated approach to deal with MDR threats.
Thus, the review ends with new connections of important bacterial components
with MDR.
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